Table 5 Summarized highlights of current BRS technologies [20]
From: Analysis of trends and prospects regarding stents for human blood vessels
| Company | Stent name | Strut backbone material |
Strut thickness (μm) | Key method | Radiopacity | Drug-eluting Property |
|---|---|---|---|---|---|---|
| Abbott | Absorb BVS | PLLA | 150 (BVS), 100 (Next gen) | Blow molding process and orientation (stretching) | 2 platinum radiopaque markers | Everolimus |
| Amaranth | Fortitude, Aptitude | PLLA | 150, 120 | Dip coating to induce linear/radial orientation | N/A | Sirolimus |
| ART | ART18Z | PDLLA | 170 (1st gen), 140–150 (2nd gen) | Annealing | N/A | None (1st gen), Sirolimus (2nd gen) |
| Arterius | ArterioSorb | PLLA | 140–100 | Die drawing to induce orientation and alignment | Radiopaque markers | Sirolimus |
| Elixir | DeSolve | PLLA | 150 (1st gen), 120 (2nd gen) | Annealing and quenching | Metallic markers | Novolimus |
| REVA medical Xenogenics | Fantom Ideal BioStent | Tyrosine PC, PAE salicylic acid | 125, 175 | Proprietary polymer | Iodine incorporated into the polymer or N/A | Sirolimus or Sirolimus + Salicylic acid |
| Envision Scientific | BIOLUTE-next | Mg alloy | 120 | Bio-corrodible metal and polymer coating | Radiopaque markers | Sirolimus |